A method for promoting fertility enhancement in a mammal is provided, comprising administering to the mammal a weight loss agent, a mitochondria-enhancing agent and a fertility support agent. Compositions for fertility enhancement are also provided.
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
A61K 36/21 - Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
C07C 50/28 - Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure
C07C 279/14 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
C07D 311/04 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring
C07D 339/04 - Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
C07D 475/04 - Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
A method of improving at least one of the following in an individual: lean mass, muscle strength, cognition, systemic inflammation levels, blood cholesterol levels, blood triglyceride levels and glucose tolerance is provided, comprising administering to the individual a multi-nutrient composition a protein, creatine, vitamin D, calcium and an n-3 fatty acid.
A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/592 - 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2
A method for promoting weight management in a mammal is provided, comprising administering to the mammal a weight loss agent and a mitochondria enhancing agent. Compositions for weight management are also provided.
A61K 31/385 - Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
This application is directed to the use of a ketogenic agent, such as 1,3-butanediol, R-β-hydroxybutyl-R-β-hydroxybutyrate, or triheptanoin, in the treatment of an individual having a lysosomal storage disease, including Pompe disease. Compositions comprising ketogenic agents and metabolic enhancing agents for treating a lysosomal storage disease are also provided.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
A61K 31/047 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
09 - Scientific and electric apparatus and instruments
41 - Education, entertainment, sporting and cultural services
Goods & Services
Downloadable computer application software for mobile phones, portable media players, and handheld computers, namely, software for use in electronic storage of data, in the field of exercise, fitness, and dietary information and instruction; pre-recorded DVDs, featuring exercise, fitness and dietary information and instruction, and related written materials, namely, instruction manuals, dietary manuals, and package inserts explaining the exercises demonstrated on the media and general information about health and fitness, all sold as a unit Providing a web site featuring on-line instruction in the field of physical exercise and nutrition and tracking progress of exercise workouts; educational services and on-line educational services, namely, providing instruction and training in the fields of exercise equipment, physical exercise and diet and nutrition, and instructional materials distributed in connection therewith; educational services, namely, instruction, training, classes, seminars, presentations, and workshops in the field of tracking progress of exercise workouts for others
09 - Scientific and electric apparatus and instruments
41 - Education, entertainment, sporting and cultural services
Goods & Services
(1) Downloadable computer application software for mobile phones, portable media players, and handheld computers, namely, software for use in electronic storage of data, in the field of exercise, fitness, and dietary information and instruction; pre-recorded DVDs, featuring exercise, fitness and dietary information and instruction, and related written materials, namely instruction manuals, dietary manuals, and package inserts explaining the exercises demonstrated on the media and general information about health and fitness, all sold as a unit. (1) Providing a web site featuring on-line instruction in the field of physical exercise and nutrition and tracking progress of exercise workouts; educational services and on-line educational services, namely, providing instruction and training in the fields of exercise equipment, physical exercise and diet and nutrition, and instructional materials distributed in connection therewith; educational services, namely, tracking progress of exercise workouts for others.
A method of improving at least one of the following in an individual: lean mass, muscle strength, cognition, systemic inflammation levels, blood cholesterol levels, blood triglyceride levels and glucose tolerance is provided, comprising administering to the individual a multi-nutrient composition a protein, creatine, vitamin D, calcium and an n-3 fatty acid.
A61P 25/00 - Drugs for disorders of the nervous system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
This application is directed to the use of a ketogenic agent, such as 1,3-butanediol, R-ß-hydroxybutyl-R-ß-hydroxybutyrate, or triheptanoin, in the treatment of an individual having a lysosomal storage disease, including Pompe disease. Compositions comprising ketogenic agents and metabolic enhancing agents for treating a lysosomal storage disease are also provided.
C07C 50/28 - Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure
C07C 59/01 - Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
C07C 69/28 - Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds
C07C 69/34 - Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
C07C 275/16 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
C07D 311/04 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring
C07D 339/04 - Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
This application is directed to the use of a ketogenic agent, such as 1,3-butanediol, R-β-hydroxybutyl-R-β-hydroxybutyrate, or triheptanoin, in the treatment of an individual having a lysosomal storage disease, including Pompe disease. Compositions comprising ketogenic agents and metabolic enhancing agents for treating a lysosomal storage disease are also provided.
C07C 275/16 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
C07C 50/28 - Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure
C07C 59/01 - Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
C07C 69/28 - Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds
C07C 69/34 - Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
C07D 311/04 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring
C07D 339/04 - Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
A method for promoting weight management in a mammal is provided, comprising administering to the mammal a weight loss agent and a mitochondria enhancing agent. Compositions for weight management are also provided.
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
The use of a composition to promote weight management in a mammal is provided. The composition comprises at least one of a weight loss agent and at least one of a mitochondria enhancing agent, wherein the weight loss agent comprises green tea extract, green coffee bean extract and forskolin and the mitochondria enhancing agent comprises beetroot extract, coenzyme Q10, alpha lipoic acid and vitamin E.
A method for promoting weight management in a mammal is provided, comprising administering to the mammal a composition comprising at least one weight loss agent and at least one mitochondria enhancing agent. The weight loss agent may be selected from the group consisting of psyllium, guar gum, capsaicin, chitosan, caffeine, garcinia cambogia, Pinus densiflora, capsaicin, yohimbre, hoodia, glucomannan, African mango, guarana, pyruvate, carnitine, beta-glucan, fucoxanthin, raspberry ketone, white kidney bean, kola nut, chromium, ginseng, psyllium, St. John's wort, dandelion, hydroxycitric acid, conjugated linoleic acid, green tea, black tea, green coffee beans extract, forskolin and bitter orange. The mitochondria enhancing agent may be selected from the group consisting of beetroot extract, nitrate, idebenone, nicotinamide riboside, elamepratide, vitamin C, vitamin D, vitamin E, thiamine, riboflavin, magnesium, calcium, phosphate, phospholipid, creatine, pyruvate, coenzyme Q10, NADH, nicotinic acid, L-camitine, dicholoracetate, curcumin, schisandrin and resveratrol. Compositions for weight management are also provided.
A method of reducing glutamate efflux from skeletal muscle by inhibiting system Xc- activity is provided. The method is useful for the treatment of statin-induced myalgia. Pharmaceutical compositions useful to treat statin-induced myalgia are also provided, as well as a kit.
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/145 - Amines, e.g. amantadine having sulfur atoms, e.g. thiurams (N—C(S)—S—C(S)—N or N—C(S)—S—S—C(S)—N)Sulfinylamines (—N=SO)Sulfonylamines (—N=SO2)
A61K 31/185 - AcidsAnhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 36/36 - Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07C 279/14 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
C07C 323/25 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
C07C 50/28 - Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure
C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
C07D 311/04 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring
C07D 339/04 - Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
14.
USE OF SYSTEM XC- INHIBITOR FOR TREATING STATIN-INDUCED MYALGIA
A method of reducing glutamate efflux from skeletal muscle by inhibiting system Xc- activity is provided. The method is useful for the treatment of statin-induced myalgia. Pharmaceutical compositions useful to treat statin-induced myalgia are also provided, as well as a kit.
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/145 - Amines, e.g. amantadine having sulfur atoms, e.g. thiurams (N—C(S)—S—C(S)—N or N—C(S)—S—S—C(S)—N)Sulfinylamines (—N=SO)Sulfonylamines (—N=SO2)
A61K 31/185 - AcidsAnhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 36/36 - Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07C 50/28 - Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure
C07C 279/14 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
C07C 323/25 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
C07D 311/04 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring
C07D 339/04 - Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
A method of improving at least one of the following in an individual: lean mass, muscle strength, cognition, systemic inflammation levels, blood cholesterol levels, blood triglyceride levels and glucose tolerance is provided, comprising administering to the individual a multi- nutrient composition a protein, creatine, vitamin D, calcium and an n-3 fatty acid.
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/59 - Compounds containing 9,10-seco-cyclopenta[a]hydro- phenanthrene ring systems
A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A method of improving at least one of the following in an individual: lean mass, muscle strength, cognition, systemic inflammation levels, blood cholesterol levels, blood triglyceride levels and glucose tolerance is provided, comprising administering to the individual a multi- nutrient composition a protein, creatine, vitamin D, calcium and an n-3 fatty acid.
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/59 - Compounds containing 9,10-seco-cyclopenta[a]hydro- phenanthrene ring systems
A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A method of treating a neuropathy, such as a recessive neuronopathy or peripheral neuropathy, in a mammal is provided. The method comprises administering to the mammal a therapeutically effective amount of exosomes genetically engineered to comprise a functional neuropeptide or nucleic acid encoding the neuropeptide.
A method of treating a central nervous system disorder in a mammal is provided. The method comprises administering to the mammal a therapeutically effective amount of non-naturally occurring exosomes engineered to comprise nucleic acid encoding a functional neuropeptide and/or the neuropeptide.
C12N 15/52 - Genes encoding for enzymes or proenzymes
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
Exosomes which are genetically modified to incorporate a functional CFTR protein and/or nucleic acid encoding a functional CFTR protein are provided, as well as the use of such genetically modified exosomes to treat CF.
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A method of treating myopathy in a mammal is provided. The method includes administering to the mammal exosomes genetically modified to incorporate a muscle protein useful to treat the myopathy or nucleic acid encoding the protein.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A method of inducing mitochondrial biogenesis in a mammal is provided. The method comprises the step of administering to the mammal an interleukin-15 or nucleic acid encoding an interleukin-15 to the mammal.
A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
Genetically modified exosomes are provided which express a nuclease genome editing system. The exosomes are useful, for example, to edit genetic defects in the treatment of genetic disease.
A method of treating a mitochondrial disease in a mammal is provided, wherein the mitochondrial disease results from a mutation in nucleic acid encoding a mitochondrial product, The method comprises administering to the mammal a therapeutically effective amount of non-naturally occurring exosomes engineered to comprise total mammalian mitochondrial RNA, nucleic acid encoding the mitochondrial product, or the functional mitochondrial product.
Exosomes which are genetically modified to incorporate a functional lysosomal protein and/or nucleic acid encoding a functional lysosomal protein are provided, as well as the use of such genetically modified exosomes to treat lysosomal storage disease.
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
A61K 8/00 - Cosmetics or similar toiletry preparations
A method of isolating exosomes from a biological sample is provided. The method includes the steps of: i) exposing the biological sample to a first centrifugation to remove cellular debris greater than about 7-10 microns in size from the sample and obtaining the supernatant following centrifugation; ii) subjecting the supernatant from step i) to centrifugation to remove microvesicles therefrom; iii) microfiltering the supernatant from step ii) and collecting the microfiltered supernatant; iv) subjecting the microfiltered supernatant from step iii) to at least one round of ultracentrifugation to obtain an exosome pellet; and v) re-suspending the exosome pellet from step iv) in a physiological solution and conducting a second ultracentrifugation in a density gradient and remove the exosome pellet fraction therefrom. The method advantageously results in exosomes that maintain integrity, stability and are essentially free from contaminating particles.
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
C07K 17/02 - Peptides being immobilised on, or in, an organic carrier
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
An exosome pellet or physiological solution comprising resuspended exosomes is provided. The exosomes are essentially free from particles having a diameter less than 20 nm or greater than 120 nm, and the exosomes comprise one or more metabolic products. The exosomes may be used to induce mitochondrial biogenesis, increase thermogenesis (browning) of subcutaneous white adipose tissue, and/or mediate other systemic effects of exercise in a mammal.
C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
C07K 17/04 - Peptides being immobilised on, or in, an organic carrier entrapped within the carrier, e.g. gel, hollow fibre
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
31.
THERAPEUTIC METHOD OF INDUCING MITOCHONDRIAL BIOGENESIS
A method of inducing mitochondrial biogenesis in a mammal is provided. The method comprises the step of administering to the mammal an interleukin-15 or nucleic acid encoding an interleukin-15 to the mammal.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
32.
THERAPEUTIC METHOD OF INDUCING MITOCHONDRIAL BIOGENESIS
A method of inducing mitochondrial biogenesis in a mammal is provided. The method comprises the step of administering to the mammal an interleukin-15 or nucleic acid encoding an interleukin-15 to the mammal.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Capturing health benefits of physical exercise in a medically useful form can treat obesity, cardiovascular disease, type 2 diabetes and cancer. Endurance exercise causes browning of white adipose tissue (WAT), and increases metabolic function by activating peroxisome proliferator-activated receptor (PPAR) gamma coactivator 1 alpha (PGC-1α), a transcriptional co-activator. Transgenic mice over-expressing PGC-1α in skeletal muscle are resistant to age-related obesity and diabetes, and have increased browning of WAT. Meteorin-like protein (Metrn1) is now identified as mediating the increased WAT browning by PGC-1α. Also, endurance exercise upregulates circulating Metrn1 levels in humans and mice. Exogenous administration of Metrn1 to mice on a high fat diet (HFD) recapitulates exercise-mediated effects in the absence of exercise: activates browning and thermogenic gene programs in WAT, increases energy expenditure, reduces body weight, increases glucose tolerance, and reduces fasting glucose level. Genes characteristic of brown fat cells upregulated by Metrnl include Ucp1, Prdm16 and Cidea.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
